+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS)



Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS)



Canadian Journal of Cardiology 26(9): E330-E335



Despite clear guideline recommendations, there is a growing body of evidence that there is suboptimal use of lipid-lowering treatment in Canadians. To assess the prevalence and types of persistent lipid abnormalities in Canadian patients receiving statin therapy. The present cross-sectional study recruited 2436 outpatients 45 years of age or older who were treated with statins by 232 physicians from 10 provinces; all underwent clinical examination and had their latest fasting lipid values while on statin therapy recorded. The median patient age was 66 years (interquartile range [IQR] 58 to 74 years), 60% were men and 80% were in the high 10-year risk category. The median low-density lipoprotein cholesterol level was 2.0 mmol/L (IQR 1.6 mmol/L to 2.5 mmol/L) and the median total cholesterol/high-density lipoprotein cholesterol ratio was 3.4 mmol/L (IQR 2.8 mmol/L to 4.1 mmol/L). However, based on the 2006 Canadian Cardiovascular Society recommendations, 37% of all patients did not have a low-density lipoprotein cholesterol level at goal or intervention target level, including 45% of high-risk category patients. The majority of patients received atorvastatin (50%) or rosuvastatin (37%) but primarily at low-to-medium doses, and a minority (14%) received additional lipid-modifying therapies. The present observational study highlights the need for more intensive treatment of lipid abnormalities, particularly among high-risk patients. Recognizing several important limitations related to the observational nature of the study, the findings suggest the possibility that, in addition to optimizing adherence, there remains an important need to titrate current statin therapy to higher doses and potentially use a combination of lipid-modifying treatments (once the statin dose has been truly maximized) to further bridge the gap between evidence-based medicine and current Canadian practice.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 055157415

Download citation: RISBibTeXText

PMID: 21076724


Related references

Prevalence of dyslipidemia in statin-treated patients in the Baltic states (Estonia, Latvia, and Lithuania): results of the Dyslipidemia International Study (DYSIS). Medicina 50(1): 44-53, 2016

Persistent dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events - Results of the DYSlipidemia International Study (DYSIS). Wiener Klinische Wochenschrift 123(19-20): 611-617, 2012

Persistent lipid abnormalities in patients with hypertension and dyslipidemia treated with statins: results of the Portuguese hypertensive subpopulation of the Dyslipidemia International Study (DYSIS). Clinical and Experimental Hypertension 37(2): 116-121, 2015

Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS). Atherosclerosis 235(2): 463-469, 2015

Prevalence of lipid abnormalities among treated patients with stable CHD: The Dyslipidemia International Study (DYSIS) II South Korea results. Atherosclerosis 241(1): E131-E132, 2015

Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International Study. Vascular Health and Risk Management 10: 225-235, 2014

The DYSlipidemia International Study DYSIS-Egypt A report on the prevalence of lipid abnormalities in Egyptian patients on chronic statin treatment. The Egyptian Heart Journal 65(3): 223-232, 2013

Results of the Dyslipidemia International Study (DYSIS)-Middle East: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment. Plos One 9(1): E84350, 2014

P202 Persistent Lipid Abnormalities In Statin Treated Patients In Spain. The Dyslipidemia International Survey Study (Dysis-Spain). Atherosclerosis Suppl.s 11(2): 58-59, 2010

Low LDL-C target achievement among treated acs patients in germany: the dyslipidemia international study (dysis) iiacs results. Atherosclerosis 241(1): E201-E202, 2015

Persistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipidemia International Study (DYSIS). Revista Portuguesa de Cardiologia 30(1): 47-63, 2011

Persistent dyslipidemia in Chinese patients treated with lipid-lowering drugs: interim results of the dyslipidaemia international study (DYSIS) China. European Heart Journal 34(Suppl 1): P4306-P4306, 2013

Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS). International Journal of Clinical Practice 68(2): 180-187, 2015

Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS). Cardiovascular Journal of Africa 24(8): 330-338, 2014

Prevalence of dyslipidaemia in statin-treated patients in Ireland: Irish results of the DYSlipidaemia International Study (DYSIS). Irish Journal of Medical Science 180(2): 343-349, 2011